News & Updates

Pre-/post-discharge sotagliflozin may reduce CV death, hospitalization in T2D patients with HF

28 Jan 2021 by

Sotagliflozin given pre- or shortly post-discharge to patients with type 2 diabetes (T2D) recently hospitalized for worsening heart failure (HF) may result in a reduced risk of cardiovascular (CV) death, hospitalization, or urgent visits for HF, according to results of the phase III SOLOIST-WHF* trial.

Pre-/post-discharge sotagliflozin may reduce CV death, hospitalization in T2D patients with HF

28 Jan 2021

SGLT2 inhibitors change blood pressure, affect renal outcomes in T2DM

28 Jan 2021

In type 2 diabetes mellitus (T2DM) patients, the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors reduces blood pressure which, in turn, influences renal outcomes, a new Japan study has found.

SGLT2 inhibitors change blood pressure, affect renal outcomes in T2DM

28 Jan 2021

COVID-19 patients with diabetes at higher risk of complications, death

28 Jan 2021 by

Diabetes is independently associated with the prognosis of the novel coronavirus disease (COVID-19), according to a study in Wuhan, China, the ground zero of the pandemic.

COVID-19 patients with diabetes at higher risk of complications, death

28 Jan 2021

Add-on vildagliptin improves outcomes in patients with diabetes, CAD

28 Jan 2021

Patients with type 2 diabetes mellitus (T2DM) and symptomatic coronary artery disease (CAD) treated with metformin fare better with the addition of vildagliptin versus glimepiride, as the former is associated with better glycaemic control and lipid profile, according to a study.

Add-on vildagliptin improves outcomes in patients with diabetes, CAD

28 Jan 2021

SGLT2i–DPP-4i combo boosts glycaemic control in T2DM

26 Jan 2021

The combination of sodium-glucose co-transporter-2 (SGLT2i) and dipeptidyl peptidase-4 (DPP-4i) inhibitors cuts postprandial hyperglycaemia and improves the quality of glycaemic variability, as opposed to monotherapy with either agent, reports a new study.

SGLT2i–DPP-4i combo boosts glycaemic control in T2DM

26 Jan 2021

COVID-19 brain complications up with diabetes, hypertension

26 Jan 2021 by

Patients with diabetes and hypertension are at an increased risk for neurologic complications from COVID-19, and this makes an already bad prognosis into worse, reports an expert at RSNA 2020.

COVID-19 brain complications up with diabetes, hypertension

26 Jan 2021

CARMELINA: Linagliptin lowers albuminuria in T2D patients with nephrotic-range proteinuria

26 Jan 2021 by

In patients with type 2 diabetes (T2D) and nephrotic-range proteinuria, treatment with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin helps reduce albuminuria burden and manage blood sugar at the same time, without increasing the risk of adverse cardiovascular or kidney events, according to data from the CARMELINA trial.

CARMELINA: Linagliptin lowers albuminuria in T2D patients with nephrotic-range proteinuria

26 Jan 2021

BMI cutoff for overweight needs readjustment in Asians, says study

26 Jan 2021 by

Body mass index (BMI) levels both above and below 25.0–29.9 kg/m2 are associated with increased mortality in a population without pre-existing disease, suggesting that the current cutoff of overweight (BMI ≥23 kg/m2) may need re-evaluation and that BMI alone may not be an accurate measure for indicating adiposity in Asians, according to a prospective cohort study in Korea.

BMI cutoff for overweight needs readjustment in Asians, says study

26 Jan 2021

Adding chemo to endocrine therapy may benefit premenopausal women with early breast cancer

25 Jan 2021 by

The addition of chemotherapy to endocrine therapy improved invasive disease-free survival (IDFS) in premenopausal women with lymph node-positive early stage hormone receptor-positive (HR+) HER2-negative (HER2-) breast cancer with recurrence score ≤25, according to early results of the phase III SWOG S1007 RxPonder* trial presented at SABCS 2020. However, the benefits did not appear to extend to postmenopausal women.

Adding chemo to endocrine therapy may benefit premenopausal women with early breast cancer

25 Jan 2021

Sotagliflozin SCORED favourably in patients with T2D, CKD

25 Jan 2021 by

Use of the sodium-glucose cotransporter 2 (SGLT2) inhibitor sotagliflozin led to a reduction in the risk of deaths from cardiovascular (CV) causes, hospitalizations for heart failure (HF), and urgent visits for HF compared with placebo among patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) regardless of the degree of albuminuria, the SCORED* trial has shown.

Sotagliflozin SCORED favourably in patients with T2D, CKD

25 Jan 2021

News & Updates

Filter by Specialty:

Specialty:

Pre-/post-discharge sotagliflozin may reduce CV death, hospitalization in T2D patients with HF

Pre-/post-discharge sotagliflozin may reduce CV death, hospitalization in T2D patients with HF

SGLT2 inhibitors change blood pressure, affect renal outcomes in T2DM

SGLT2 inhibitors change blood pressure, affect renal outcomes in T2DM

COVID-19 patients with diabetes at higher risk of complications, death

COVID-19 patients with diabetes at higher risk of complications, death

Add-on vildagliptin improves outcomes in patients with diabetes, CAD

Add-on vildagliptin improves outcomes in patients with diabetes, CAD

SGLT2i–DPP-4i combo boosts glycaemic control in T2DM

SGLT2i–DPP-4i combo boosts glycaemic control in T2DM

COVID-19 brain complications up with diabetes, hypertension

COVID-19 brain complications up with diabetes, hypertension

CARMELINA: Linagliptin lowers albuminuria in T2D patients with nephrotic-range proteinuria

CARMELINA: Linagliptin lowers albuminuria in T2D patients with nephrotic-range proteinuria

BMI cutoff for overweight needs readjustment in Asians, says study

BMI cutoff for overweight needs readjustment in Asians, says study

Adding chemo to endocrine therapy may benefit premenopausal women with early breast cancer

Adding chemo to endocrine therapy may benefit premenopausal women with early breast cancer

Sotagliflozin SCORED favourably in patients with T2D, CKD

Sotagliflozin SCORED favourably in patients with T2D, CKD